Cellular Therapy in Oncology Market - Global Industry Analysis, Size, Growth, Trends and Forecast 2017 - 2025


Transparency Market Research

$ 5795

Corrections in administrative and repayment arrangements, just as the execution of contingent endorsement approaches for RM, will further drive the market by expediting item dispatches. Furthermore, upgrades in cell culturing procedures close by the utilization of various undifferentiated cells, for example, fat determined undeveloped cells (ADSCs), mesenchymal immature microorganisms (MSCs), and induced Pluripotent Stem Cell will reinforce the market with prevalent treatment choices for non-oncological conditions, for example, neurological, musculoskeletal, and dermatological conditions.

China, India, Japan, Korea, and Brazil are emerging markets for cell therapy instruments, and this is an emerging trend for players in the global cellular therapy in oncology market. These markets brag relatively permissive gauges and government guidelines instead of created markets in North America and the EU, and in this way offer huge development potential for suppliers. Be that as it may, the mind-boggling expense of cell-based research and the low achievement rate is relied upon to restrain development in the global cellular therapy in oncology market.

  • Manufacturing Automation by methods for usage of IT arrangements and single-use manufacturing systems for optimizing little volume, high-esteem manufacturing of novel cell treatments are in this manner reducing an opportunity to market radically.
  • Wide-ranging remedial concentration crosswise over both oncology and non-oncology conditions is fuelling cellular therapy in oncology market development. With excess of 959 ongoing regenerative medicine clinical preliminaries, the market finds opportunity crosswise over both foundational microorganism and non-immature microorganism based treatments.
  • Emerging Business Models, which help market players, center around scholarly and inquire about joint efforts close by industry coordinated efforts to help restorative and mechanical innovations.
  • Therapeudic Combination Therapies, which help to improve reaction rates among patients, while reducing the span of reaction. These treatments likewise find application in identifying the correct patient just as predicting the insusceptible reaction in disease patients.

Cellular therapy is also known as cytotherapy or cell therapy. Cellular therapy (CT) is the transplantation of cellular material into human body to repair or replace damaged tissue and damaged cells. Advancement in technology, development of innovative products, and growth in the number of research activities have helped in the discovery of several types of cells that are likely to be used in the treatment or therapy of various conditions and diseases. Several cells such as hematopoietic stem cells (HSC), mesenchymal stem cells, skeletal muscle stem cells, dendritic cells, pancreatic islet cells, and lymphocytes can be used in cellular therapy. HSC is extensively used in cellular therapy. Cellular therapy is used to treat various types of cancers, infectious diseases, autoimmune diseases, and urinary problems. The therapy also helps patients rebuild damaged cartilage in joints, improve a weakened immune system, and repair spinal cord injuries. Moreover, it also helps treat neurological disorders. Cellular cancer therapy has various approaches as the cell can be designed to stimulate the patient’s immune system (T cells or natural killer cells) to kill cancer cells, or to replace most of the patient’s immune system to enhance their immune response to cancer cells, or to directly find and kill the cancer cells.

The global cellular therapy in oncology market has been classified based on cancer type and geography. In terms of cancer type, the market has been categorized into blood cancer, prostate cancer, pancreatic cancer, brain cancer, and other cancer. The blood cancer segment accounts for a major share of cellular therapy in oncology market. Increasing prevalence of prostate cancer is expected propel the segment in the near future. According to WHO statistics, 8.2 million people die each year due to cancer which estimates about 13% of all death worldwide. There are more than 100 types of cancers that require unique diagnoses and therapies. This increases the demand for cellular therapy in oncology in near future.

Geographically, the cellular therapy in oncology market has been segmented into five major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. In terms of revenue, North America dominates the cellular therapy in oncology market followed by Europe. The market in Asia Pacific and Latin America is developing. This trend is expected to continue during the forecast period. Availability of large patient pool, expansion of the health care industry, and rise in government investment to improve the health care industry are anticipated to propel the market in these regions. The cellular therapy in oncology market in countries such as Brazil, China, and India are projected to expand at substantial growth rate during the forecast period due to rise in awareness among the population about the usage of cellular therapy to treat various types of cancers and rapid innovations in cellular therapy.

Increasing prevalence of various cancers, affordability of cellular therapy in cancer drugs, high adoption in developed markets, and development of innovative drugs are other factors driving the cellular therapy in oncology market. High competition among existing players, high risks of failure, severity and complications involved in cellular therapy due to misdiagnosis, and lack of awareness among the rural population in underdeveloped and developing economies are likely to inhibit the market.

Major players operating in the cellular therapy in oncology market include Alkem Laboratories Limited, Amgen, Inc., Bayer AG, Sanofi, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd, Cipla, Inc., Merck & Co., Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information:

  • Tailwinds and headwinds molding the market’s trajectory
  • Market segments based on products, technology, and applications
  • Prospects of each segment
  • Overall current and possible future size of the market
  • Growth pace of the market
  • Competitive landscape and key players’ strategies

The main aim of the report is to:

  • Enable key stakeholder’s in the market bet right on it
  • Understand the opportunities and pitfalls awaiting them
  • Assess the overall growth scope in the near term
  • Strategize effectively with respect to production and distribution

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.